NCT01649869: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01649869 |
|---|---|
| Title | A Phase II Randomized and Controlled Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 24, 2015 |
| Completion date | Dec. 24, 2019 |
| Required reporting date | Dec. 23, 2020, midnight |
| Actual reporting date | Dec. 23, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |